TNBC remains one of the most challenging breast cancer subtypes to treat, mainly due to its intrinsic cellular heterogeneity, the absence of key actionable endocrine or HER2 targets, and a propensity for early recurrence and metastasis. Here, ERBB2 is linked to breast cancer.